Ethylbromazolam

The following information was compiled in October 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: Ethylbromazolam is a designer benzodiazepine and is structurally similar to other known triazolobenzodiazepines (e.g., bromazolam, flubromazolam, phenazolam). Ethylbromazolam has been previously reported in drug materials in Australia and New Zealand.^1-3 Ethylbromazolam was first identified by our laboratory in July 2025 and confirmed after acquiring standard reference material.

Sample Source: Toxicology UK (United Kingdom)

Sample Appearance: Blood specimen

Pharmacology: The activity and potency of ethylbromazolam has not been explicitly studied; however, due to structural similarity to other designer benzodiazepines such as bromazolam, it is assumed that ethylbromazolam functions by positive allosteric modulation of the GABA_A receptor.⁴

Toxicology: Ethylbromazolam has been detected in thirteen toxicology cases to date at the CFSRE.

Drug Materials: Ethylbromazolam has been detected in six drug materials to date at the CFSRE.

Demographics / Geographics: The first toxicology specimen originated from the United Kingdom and ethylbromazolam was identified alongside methamphetamine, cocaine, and etizolam. Ethylbromazolam has also been detected in the United States in Pennsylvania, California, New England, and beyond.

Legal Status: Ethylbromazolam is not currently scheduled in the United States.

Class:

Benzodiazepine

Appearance:

Blood specimen

Formula:

C18H15BrN4

MW:

367.2

[M+]:

366

[M+H]+:

367.0553

IUPAC:

8-bromo-1-ethyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

Report Date:

October 10, 2025